Truist Securities Reiterates Hold on Inari Medical, Lowers Price Target to $61
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has reiterated a Hold rating on Inari Medical (NASDAQ:NARI) and lowered the price target from $63 to $61.
February 29, 2024 | 2:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities has maintained a Hold rating on Inari Medical but reduced the price target from $63 to $61.
The reduction in the price target by Truist Securities suggests a slightly less optimistic outlook on Inari Medical's stock value in the short term. This adjustment could lead to a negative perception among investors, potentially causing a short-term decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100